Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study.
Dose tapering
Effectiveness
Giant cell arteritis
Large-vessel vasculitis
Spacing
Tocilizumab
Treatment
Vasculitis
Journal
Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
13
11
2022
revised:
01
02
2023
accepted:
06
02
2023
pmc-release:
01
04
2024
pubmed:
13
2
2023
medline:
4
3
2023
entrez:
12
2
2023
Statut:
ppublish
Résumé
To evaluate the feasibility of tocilizumab tapering and withdrawal in patients with giant cell arteritis (GCA). GCA patients eligible for tocilizumab were prospectively enrolled. Tocilizumab was administered weekly for the first 12 months, every-other-week for an additional 12 months, then discontinued. Relapses on tocilizumab were managed with temporary increases in systemic glucocorticoids or addition of methotrexate. Primary outcome was relapse-free survival at month 6 after tocilizumab suspension. Relapse-free survival on tocilizumab, imaging response, and adverse events were evaluated. 23 GCA patients were enrolled. Reasons for tocilizumab start were relapse (n = 14), persistence of activity (n = 5), or steroid-related adverse events (n = 4). At tocilizumab start, two patients were on methotrexate, which was maintained. Fourteen patients had extracranial vascular involvement on Tocilizumab tapered over a two-year period was effective to induce and maintain remission in GCA. Relapses on tocilizumab were minor and responded to incremental changes in therapy. A significant proportion of patients relapsed in the 6 months after therapy suspension.
Identifiants
pubmed: 36774660
pii: S0049-0172(23)00014-8
doi: 10.1016/j.semarthrit.2023.152174
pmc: PMC9992325
mid: NIHMS1873790
pii:
doi:
Substances chimiques
tocilizumab
I031V2H011
Methotrexate
YL5FZ2Y5U1
Fluorodeoxyglucose F18
0Z5B2CJX4D
Glucocorticoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
152174Subventions
Organisme : Intramural NIH HHS
ID : Z99 AR999999
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Références
Rheumatol Int. 2018 Apr;38(4):569-577
pubmed: 29124397
Medicine (Baltimore). 2014 Jul;93(5):194-201
pubmed: 25181312
Arthritis Rheum. 2006 Oct;54(10):3310-8
pubmed: 17009270
N Engl J Med. 2017 Jul 27;377(4):317-328
pubmed: 28745999
JAMA. 2020 Sep 8;324(10):993-994
pubmed: 32897333
Ther Adv Musculoskelet Dis. 2022 Jul 22;14:1759720X221113747
pubmed: 35898567
Ann Rheum Dis. 2015 Jan;74(1):129-35
pubmed: 24095936
Semin Arthritis Rheum. 2021 Apr;51(2):387-394
pubmed: 33607384
Arthritis Rheum. 2003 Oct 15;49(5):703-8
pubmed: 14558057
Ann Rheum Dis. 2020 Jan;79(1):19-30
pubmed: 31270110
Rheumatology (Oxford). 2021 Aug 2;60(8):3851-3861
pubmed: 33831144
Arthritis Rheumatol. 2021 Aug;73(8):1349-1365
pubmed: 34235884
Rheumatology (Oxford). 2022 Jul 6;61(7):2915-2922
pubmed: 34718434
Arthritis Res Ther. 2020 Apr 28;22(1):96
pubmed: 32345367
Arthritis Rheum. 2003 Dec;48(12):3522-31
pubmed: 14674004
Nat Rev Rheumatol. 2020 Sep;16(9):481-495
pubmed: 32759996
Rheumatology (Oxford). 2016 Feb;55(2):347-56
pubmed: 26385368
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3886-3902
pubmed: 33942141
Arthritis Rheumatol. 2023 Jan;75(1):98-107
pubmed: 35792044
Rheumatology (Oxford). 2021 Sep 1;60(9):4384-4389
pubmed: 33369678
Arthritis Rheumatol. 2018 Mar;70(3):439-449
pubmed: 29145713
Clin Exp Rheumatol. 2022 Nov 2;:
pubmed: 36377586
Rheum Dis Clin North Am. 2016 Feb;42(1):75-90, viii
pubmed: 26611552
Ann Rheum Dis. 2018 May;77(5):636-643
pubmed: 29358285
Scand J Rheumatol. 2022 Jan;51(1):59-66
pubmed: 33913792